Recent Updates
Recently added Catalysts

Enovis Corporation

ENOVFDA catalysts, PDUFA dates & pipeline intelligence
$26.23
▼ -0.87 · -3.21%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ENOV financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $16.7052W HIGH $31.66
Volume
788.66 K
Value Traded
20.75 M
Short % Float
18.77%
Days to Cover
7.3
-5.1%Week
+26.78%1 Month
+0.19%3 Month
+6.67%6 Month
-68.19%5 Year
-37.49%All Time

Cash Data

Unlock ENOV cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.51 B
EPS (TTM)
-9.14
P/E Ratio
-
Ent. Value
2.79 B
Total Shares
57.67 M
Float Shares
56.26 M
Insiders
2.48%
Institutions
123.13%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every ENOV catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ENOV Catalyst Timeline

Dated clinical, regulatory and corporate events for Enovis Corporation

Unlock the full ENOV catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ENOV actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2004-10-26Lidocaine Hydrochloride And Epinephrine (epinephrine) PDUFA Date ApprovedPDUFA
Unlock all ENOV historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 77%
Micro Cap
(rank 557 of 723)
Percentile Rank
Showing 0 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the ENOV pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ENOV program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every ENOV trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ENOV insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Lalor Angela SDirectorBuy 880 34,997 held$28.27 11/13/2026
Unlock the full ENOV insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PROSIGHT MANAGEMENT, LP 0.9 % 4.89 M 267.43 K
Unlock every fund holding ENOV
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ENOV
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ENOV ownership
Insider and institutional ownership, quarter by quarter.

ENOV Short Interest

Shares sold short, counted twice a month.

18.77%
Short % of Float
of tradable shares sold short
10.6M
Shares Sold Short
-9.8% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
1.5M
Avg Daily Volume
the average used for days to cover
Unlock ENOV short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ENOV option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ENOV option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ENOV options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ENOV ranks across every disease it competes in

Competitive Position is a premium feature
See how ENOV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ENOV News

ENOV
Nov 12, 2026
ENOVConferences/Events

Enovis to Present at the Annual Jefferies Global Healthcare Conference in London

Enovis Corporation announced its participation in the Annual Jefferies Global Healthcare Conference in London, scheduled for November 17, 2026. The presentation will be led by members of the management team at 11:30 a.m. GMT. A live audio webcast and replay will be accessible on the company's website.

Read more →
ENOV
Nov 12, 2026
ENOVConferences/Events

Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London

Enovis Corporation will present at the Annual Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation is scheduled for 11:30 a.m. GMT and will be available via a live audio webcast. Enovis is dedicated to developing innovative medical technology solutions that enhance patient outcomes.

Read more →
ENOV
Nov 5, 2026
ENOVGeneral
▲ +17.2%on this news

ENOVIS Announces Third Quarter 2026 Results

Enovis Corporation reported third-quarter 2026 net sales of $559 million, reflecting a 2% increase year-over-year. The company raised its full-year guidance for adjusted EBITDA and earnings per share. Reconstructive sales grew by 6%, while the Prevention & Recovery segment saw a slight decline. Enovis also announced a new $200 million share repurchase authorization.

Read more →
ENOV
Oct 8, 2026
ENOVConferences/Events

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Enovis Corporation will hold a conference call on November 5, 2026, to discuss its third quarter financial results. The call will begin at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning. Investors can access the call via a live webcast on the company's website.

Read more →
ENOV
Sep 22, 2026
ENOVGeneral

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

Enovis has become the first industry partner to sponsor multiple registries within the AAOS Registry Program, expanding its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry. This collaboration aims to enhance data collection and improve patient care in shoulder and elbow treatments. The initiative is expected to provide valuable insights into treatment patterns and outcomes.

Read more →
ENOV
Sep 1, 2026
ENOVGeneral
▼ -16.5%on this news

eCential Robotics Announces Binding Offer from Enovis

eCential Robotics has announced a binding offer from Enovis Corporation to acquire the company. This acquisition aims to enhance Enovis' technology portfolio with eCential's robotic solutions, which are already FDA-cleared for spine surgery. The transaction is expected to close in Q4 2026, pending regulatory approvals. Both companies express optimism about the potential for improved surgical outcomes and innovation.

Read more →
ENOV
Sep 1, 2026
ENOVGeneral
▼ -16.5%on this newsshared move

Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics

Enovis Corporation has announced a binding offer to acquire eCential Robotics for €155 million, enhancing its surgical robotics capabilities. This acquisition aims to improve surgical precision and streamline workflows, with a center of excellence planned in Grenoble, France. The deal is expected to close by year-end 2026, pending regulatory approvals.

Read more →
ENOV
Aug 31, 2026
ENOVConferences/Events
▼ -16.5%on this newsshared move

Enovis to Participate in the 2026 Wells Fargo Healthcare Conference

Enovis Corporation announced its participation in the 2026 Wells Fargo Healthcare Conference, scheduled for September 8, 2026. CEO Damien McDonald and CFO Ben Berry will engage in a fireside chat at 1:30 p.m. Eastern Time. The event will be accessible via a live audio webcast on the company's website.

Read more →
ENOV
Aug 6, 2026
ENOVGeneral
▼ -12.8%on this news

Enovis Announces Second Quarter 2026 Results

Enovis Corporation reported its second-quarter 2026 financial results, showcasing a 3% increase in net sales and an 8% growth in Reconstructive sales. The company reaffirmed its full-year guidance for revenue and adjusted EBITDA, indicating confidence in its operational improvements. However, it also acknowledged challenges, including a net loss and a decline in P&R sales.

Read more →
ENOV
Jul 17, 2026
ENOVConferences/Events

Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

Enovis Corporation will host an investor conference call on August 6th, 2026, to discuss its second quarter financial results. The call will begin at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning. Investors can access the call via a dedicated link on the Enovis website.

Read more →
ENOV
Jul 13, 2026
ENOVGeneral

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

Enovis Corporation has launched CT-RevitL, a next-generation laser therapy system for veterinary care in the U.S. This system enhances clinical performance and simplifies treatment delivery for veterinary teams. With a foundation of over 150 studies on photobiomodulation therapy, CT-RevitL aims to improve patient outcomes and support practice growth. It is now available in the U.S. with plans for international rollout.

Read more →
ENOV
Jun 8, 2026
ENOVGeneral

Enovis Launches Spinamic Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

Enovis Corporation has launched the DonJoy Spinamic Hybrid Scoliosis Brace, designed to merge the corrective capabilities of traditional rigid braces with the comfort of dynamic options. The brace can be fitted in 10 sizes and utilizes an adjustable three-point pressure system to enhance wearability and compliance among adolescents with adolescent idiopathic scoliosis (AIS). Currently available in the U.S., the Spinamic brace aims to improve treatment outcomes while reducing the psychological burden often associated with traditional bracing methods. Enovis is also seeking regulatory clearance in additional markets worldwide.

Read more →
ENOV
May 7, 2026
ENOVGeneral
▲ +9.7%on this news

Enovis Announces First Quarter 2026 Results

Enovis Corporation reported a 5% increase in first-quarter sales for 2026, driven by an 11% growth in Reconstructive sales. Despite a net loss of $8 million, the company reaffirmed its full-year financial guidance, highlighting confidence in its innovation-led strategy. The results reflect stable market conditions and successful new product introductions.

Read more →
ENOV
Apr 10, 2026
ENOVConferences/Events

Enovis to Host First Quarter 2026 Results Conference Call on May 7th

Enovis Corporation will hold a conference call on May 7, 2026, to discuss its first quarter financial results. The call will be accessible via a live webcast and will include an earnings press release. Investors can participate by dialing in or accessing the webcast through the company's website.

Read more →
ENOV
Feb 26, 2026
ENOVGeneral
▲ +13.9%on this news

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Corporation reported its financial results for Q4 and full year 2025, showing a 3% increase in Q4 net sales and a 7% increase for the full year. However, the company faced a substantial net loss of $1,182 million, largely due to a goodwill impairment charge. Looking ahead, Enovis expects revenue growth of 4-6% for 2026, with adjusted EBITDA projected between $425-435 million.

Read more →
ENOV
Feb 26, 2026
ENOVGeneral
▲ +13.9%on this newsshared move

Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Corporation reported its financial results for Q4 and full year 2025, showing a 3% increase in net sales for Q4 and a 7% increase for the full year. However, the company faced a substantial net loss of $519 million in Q4 due to a goodwill impairment charge. Looking ahead, Enovis expects revenue growth of 4-6% for 2026, with adjusted EBITDA projected between $425-435 million.

Read more →
ENOV
Feb 3, 2026
ENOVConferences/Events

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Enovis Corporation will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. The event will take place in Snowbird, Utah, showcasing Enovis's commitment to innovation in medical technology. The company focuses on developing solutions that improve patient outcomes and enhance surgical efficiency.

Read more →
ENOV
Jan 23, 2026
ENOVConferences/Events

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th

Enovis Corporation will host an investor conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will begin at 8:30 a.m. Eastern Time, with a press release issued earlier that morning. Investors can access the call via a dedicated link on the company's website.

Read more →
ENOV
Jan 8, 2026
ENOVConferences/Events

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Enovis Corporation (NYSE: ENOV) has announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will occur at 4:30 p.m. PST and will be accessible via a live audio webcast. Enovis is known for creating clinically differentiated medical solutions aimed at enhancing patient lives. The company emphasizes transparency by routinely sharing material information through various channels, including its Investor Relations website.

Read more →
ENOV
Jan 6, 2026
ENOVGeneral

Enovis Appoints Oliver Engert as Chief Administrative Officer

Enovis Corporation has appointed Oliver Engert as Chief Administrative Officer, effective immediately. In this newly created role, Engert will focus on strategy development and operational efficiency to support the company's growth. CEO Damien McDonald expressed confidence in Engert's ability to drive success and improve patient care through his extensive experience.

Read more →

About Enovis Corporation

Lewisville, TX 7,802 employees enovis.com
Headquarters2900 LAKE VISTA DRIVE, LEWISVILLE, TX, 75067
BIOPHARMAWATCH ELITE
Trade the next ENOV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime